{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:49:01Z","timestamp":1792511341625,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.critrevonc.2025.105014","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:29:08Z","timestamp":1762597748000},"page":"105014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["PARP inhibitor-based combination therapies: Enriching synergistic forces against BRCA-mutated metastatic breast cancer"],"prefix":"10.1016","volume":"217","author":[{"given":"Pinchao","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4593-3918","authenticated-orcid":false,"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.critrevonc.2025.105014_bib1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105014_bib2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.21037\/cco-19-230","article-title":"Integrating PARP inhibitors into the management of breast cancer: where are we?","volume":"10","author":"Azim","year":"2021","journal-title":"Chin. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105014_bib3","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1158\/1078-0432.CCR-24-0428","article-title":"Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1\/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105014_bib4","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-21-3045","article-title":"Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer","volume":"28","author":"Batalini","year":"2022","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105014_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00140","article-title":"Cyclin-dependent kinase 4\/6 inhibitor outcomes in patients with advanced breast cancer carrying germline pathogenic variants in DNA repair-related genes","author":"Bruno","year":"2022","journal-title":"JCO Precis Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105014_bib6","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.3390\/ijms19123793","article-title":"Combining PARP inhibition, radiation, and immunotherapy: a possible strategy to improve the treatment of cancer?","volume":"19","author":"C\u00e9saire","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105014_bib7","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1158\/1078-0432.CCR-10-0527","article-title":"\"Contextual\" synthetic lethality and\/or loss of heterozygosity: tumor hypoxia and modification of DNA repair","volume":"16","author":"Chan","year":"2010","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105014_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105014_bib9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41580-023-00640-9","article-title":"Structural and functional complexity of HSP90 in cellular homeostasis and disease","volume":"24","author":"Chiosis","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105014_bib10","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1038\/s41467-020-16142-7","article-title":"Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer","volume":"11","author":"Chopra","year":"2020","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.105014_bib11","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1158\/1078-0432.CCR-17-0703","article-title":"Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors","volume":"23","author":"Dhawan","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105014_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113580","article-title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): final overall survival results from a randomized phase 3 trial","volume":"200","author":"Di\u00e9ras","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105014_bib13","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.105014_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2016.10.010","article-title":"PARP inhibitor combination therapy","volume":"108","author":"Dr\u00e9an","year":"2016","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105014_bib15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","article-title":"Olaparib monotherapy as primary treatment in unselected triple negative breast cancer","volume":"32","author":"Eikesdal","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105014_bib16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nrc2054","article-title":"Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations","volume":"7","author":"Fackenthal","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105014_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188849","article-title":"Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low","volume":"1878","author":"Fan","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105014_bib18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s13048-023-01313-z","article-title":"BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy","volume":"16","author":"Farokhi Boroujeni","year":"2023","journal-title":"J. Ovarian Res."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.105014_bib19","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.20.01200","article-title":"Mutations in BRCA1\/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis","volume":"39","author":"Fasching","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105014_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-014-3085-5","article-title":"Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer","volume":"147","author":"Feng","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105014_bib21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105014_bib22","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.3390\/ijms20143390","article-title":"Platinum salts in patients with breast cancer: a focus on predictive factors","volume":"20","author":"Garutti","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105014_bib23","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA a Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2025.105014_bib24","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3389\/fimmu.2017.00961","article-title":"Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells","volume":"8","author":"Gibbons Johnson","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.105014_bib25","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-4221","article-title":"Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER+\/HER2- breast cancer and selected genomic alterations: results of the DOLAF trial","author":"Guiu","year":"2025","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105014_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106162","article-title":"Cell cycle checkpoints and beyond: Exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer","volume":"178","author":"Gupta","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105014_bib27","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1186\/s12885-019-6121-3","article-title":"Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib","volume":"19","author":"de Haan","year":"2019","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105014_bib28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.annonc.2021.11.018","article-title":"Veliparib monotherapy following carboplatin\/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial","volume":"33","author":"Han","year":"2022","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105014_bib29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/annonc\/mdx505","article-title":"Veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in patients with BRCA1\/2 locally recurrent\/metastatic breast cancer: randomized phase II study","volume":"29","author":"Han","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105014_bib30","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/cac2.12358","article-title":"Breast cancer: an up-to-date review and future perspectives","volume":"42","author":"Hong","year":"2022","journal-title":"Cancer Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105014_bib31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2025.105014_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108280","article-title":"Therapeutics targeting the metastatic breast cancer bone microenvironment","volume":"239","author":"Ihle","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105014_bib33","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2017.77.2665","article-title":"Concurrent veliparib with chest wall and nodal radiotherapy in patients with inflammatory or locoregionally recurrent breast cancer: the TBCRC 024 phase I multicenter study","volume":"36","author":"Jagsi","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105014_bib34","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","article-title":"Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.critrevonc.2025.105014_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113812","article-title":"Radiation-guided nanoparticles enhance the efficacy of PARP inhibitors in primary and metastatic BRCA1-deficient tumors via immunotherapy","volume":"383","author":"Khoury","year":"2025","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.105014_bib36","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.105014_bib37","doi-asserted-by":"crossref","first-page":"12069","DOI":"10.1021\/acs.jmedchem.3c00640","article-title":"Discovery, synthesis, and evaluation of novel dual inhibitors of a vascular endothelial growth factor receptor and poly(ADP-Ribose) polymerase for BRCA wild-type breast cancer therapy","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105014_bib38","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1038\/s41598-021-82990-y","article-title":"BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression","volume":"11","author":"Li","year":"2021","journal-title":"Sci. Rep."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105014_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181062","article-title":"BRCAness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality","volume":"134","author":"Li","year":"2024","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105014_bib40","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-16-0198","article-title":"BRCA1-mutated estrogen receptor-positive breast cancer shows BRCAness, suggesting sensitivity to drugs targeting homologous recombination deficiency","volume":"23","author":"Lips","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105014_bib41","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41591-021-01331-8","article-title":"Evolution of delayed resistance to immunotherapy in a melanoma responder","volume":"27","author":"Liu","year":"2021","journal-title":"Nat. Med."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105014_bib42","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.ejca.2013.05.020","article-title":"A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer","volume":"49","author":"Liu","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105014_bib43","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijrobp.2020.09.032","article-title":"Combination of olaparib and radiation therapy for triple negative breast cancer: preliminary results of the RADIOPARP phase 1 trial","volume":"109","author":"Loap","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105014_bib44","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","article-title":"Targeting WEE1 kinase in Cancer","volume":"37","author":"Matheson","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105014_bib45","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/annonc\/mdw672","article-title":"Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer","volume":"28","author":"Matulonis","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105014_bib46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-015-1733-1","article-title":"Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study","volume":"122","author":"Mehta","year":"2015","journal-title":"J. Neurooncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105014_bib47","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1158\/1078-0432.CCR-24-1948","article-title":"Antitumor activity and biomarker analysis for TROP2 antibody-drug conjugate datopotamab deruxtecan in patient-derived breast cancer xenograft models","volume":"31","author":"Meric-Bernstam","year":"2025","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105014_bib48","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1158\/1535-7163.MCT-19-0520","article-title":"PARP1 inhibition radiosensitizes models of inflammatory breast cancer to ionizing radiation","volume":"18","author":"Michmerhuizen","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105014_bib49","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1001\/jamaoncol.2023.7322","article-title":"PARP inhibitors for breast cancer treatment: a review","volume":"10","author":"Morganti","year":"2024","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105014_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-023-00840-4","article-title":"The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment","volume":"21","author":"Morrison","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105014_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235025","article-title":"Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells","volume":"16","author":"Moustafa","year":"2021","journal-title":"PLOS One"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105014_bib52","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s40265-020-01394-w","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in hormone-positive breast cancer","volume":"80","author":"Nunnery","year":"2020","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105014_bib53","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa1011418","article-title":"Iniparib plus chemotherapy in metastatic triple-negative breast cancer","volume":"364","author":"O'Shaughnessy","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"34","key":"10.1016\/j.critrevonc.2025.105014_bib54","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1200\/JCO.2014.55.2984","article-title":"Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer","volume":"32","author":"O'Shaughnessy","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105014_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2021.07.008","article-title":"The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors","volume":"29","author":"Palve","year":"2022","journal-title":"Cell Chem. Biol."},{"issue":"362","key":"10.1016\/j.critrevonc.2025.105014_bib56","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105014_bib57","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3724\/abbs.2022153","article-title":"Triple kill: DDR inhibitors, radiotherapy and immunotherapy leave cancer cells with no escape","volume":"54","author":"Qiu","year":"2022","journal-title":"Acta Biochim. Biophys. Sin."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105014_bib58","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105014_bib59","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105014_bib60","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(22)00739-2","article-title":"Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"24","author":"Rodler","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.105014_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP Inhibitors: Clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105014_bib62","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41580-019-0133-3","article-title":"The Hsp70 chaperone network","volume":"20","author":"Rosenzweig","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105014_bib63","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/s41467-023-42736-y","article-title":"Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4\/6 inhibitors in treatment-refractory ER+ breast cancer","volume":"14","author":"Saatci","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105014_bib64","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105014_bib65","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-018-0850-9","article-title":"Therapeutic landscape in mutational triple negative breast cancer","volume":"17","author":"Shi","year":"2018","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105014_bib66","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.tranon.2019.07.013","article-title":"Gene alterations in triple-negative breast cancer patients in a phase I\/II study of eribulin and olaparib combination therapy","volume":"12","author":"Shimomura","year":"2019","journal-title":"Transl. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105014_bib67","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/PPO.0000000000000561","article-title":"DNA damage repair inhibitors-combination therapies","volume":"27","author":"Smith","year":"2021","journal-title":"Cancer J."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.105014_bib68","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-16-2714","article-title":"Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: california cancer consortium trial NCT01149083","volume":"23","author":"Somlo","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105014_bib69","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1042\/BST20191092","article-title":"Systems approach to rational combination therapy: PARP inhibitors","volume":"48","author":"Sun","year":"2020","journal-title":"Biochem Soc Trans."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105014_bib70","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1158\/1078-0432.CCR-23-2513","article-title":"Phase II DORA study of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer","volume":"30","author":"Tan","year":"2024","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105014_bib71","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105014_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188907","article-title":"An overview of the research progress of BRCA gene mutations in breast cancer","volume":"1878","author":"Wan","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105014_bib73","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ctrv.2018.05.014","article-title":"Emerging therapeutic modalities of PARP inhibitors in breast cancer","volume":"68","author":"Wang","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.105014_bib74","article-title":"Pan-cancer analysis of PARP1 alterations as biomarkers in the prediction of immunotherapeutic effects and the association of its expression levels and immunotherapy signatures","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105014_bib75","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13046-021-01930-w","article-title":"Efficacy and mechanism of the combination of PARP and CDK4\/6 inhibitors in the treatment of triple-negative breast cancer","volume":"40","author":"Zhu","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105014_bib76","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s40425-019-0680-3","article-title":"A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses","volume":"7","author":"Zimmer","year":"2019","journal-title":"J. Immunother. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T19:43:45Z","timestamp":1768333425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":76,"alternative-id":["S1040842825004020"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105014","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PARP inhibitor-based combination therapies: Enriching synergistic forces against BRCA-mutated metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105014"}}